The Phase 1a trial of CAR19.20.22 CAR T-cells, sponsored by the University of Maryland, aims to address the unmet medical need for patients with relapsed/refractory B-cell lymphomas, particularly those expressing multiple target antigens. The market for CAR T-cell therapies is expanding, with significant competition from existing therapies such as Kymriah and Yescarta. The success of this trial could position the University of Maryland as a key player in the CAR T-cell landscape, particularly if the asset demonstrates superior efficacy and safety profiles. Given the increasing demand for innovative therapies in oncology, successful outcomes may lead to strategic partnerships or licensing opportunities with larger biopharmaceutical companies.